Hayden E. Klein

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.

Patients aged 30 to 40 years with type 1 diabetes had the highest risk of sudden cardiac death, according to 2010 data from Denmark.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.

Long-term data suggest stress echocardiography can uncover impaired exercise capacity and predict worse outcomes in patients.

After 8 months of treatment with mavacamten, 5% of patients developed new atrial fibrillation or flutter and 4% developed heart failure.

A case-crossover study found that extreme heat increased mortality between 10% and 18%, with higher risks in vulnerable groups.

Svetlana Barbarash, MD, outlines the lack of cardiologists and transplant services in Las Vegas and the policy changes needed to close gender gaps in care.

Onasemnogene abeparvovec-brve is now the first gene replacement therapy approved for spinal muscular atrophy in patients 2 years and older.

Svetlana Barbarash, MD, explains how better education, digital monitoring tools, and coordinated care can improve arrhythmia detection and outcomes.

Research shows a sharp rise in bisphenol-attributable metabolic disease since 2000, with annual costs exceeding $250 billion in North America.

Semaglutide and tirzepatide led to the most weight loss across 22 trials, while liraglutide remains a cost-effective alternative as its patent expires.

Updated guidelines set lower systolic blood pressure goals, expanded risk-based treatment, and call for stronger implementation to close care gaps.

Researchers urged caution in interpreting DECAF Trial results that suggest daily coffee intake is linked to a lower risk of atrial fibrillation recurrence.

The trial did not meet its primary end point for reducing plaque progression.

Combining 3 standard therapies into a single pill improved outcomes for adults with heart failure with reduced ejection fraction.

New research suggests stress cardiac MRI could help diagnose angina and improve quality of life for patients whose arteries appear clear on angiography.

Only 4% of NIH prevention projects target health disparities, revealing a major gap between equity research and real-world implementation.

In a phase 3 trial, the investigational oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by nearly 60% in adults with or at risk for ASCVD.

Experts at AHA 2025 outlined how digital tools, inclusive trials, and safer deprescribing can reshape cardiovascular care for aging adults.

Research shows how low-dose aspirin, lifestyle habits, and the Life’s Essential 8 checklist can affect cardiovascular risk in patients with type 2 diabetes.

Lisa Taylor-Swanson, PhD, explains how including Indigenous and Hispanic women in conversations around menopause care helps fine-tune interventions.

Despite social media frenzy, there is limited evidence around testosterone’s impact on muscle, mood, and other menopausal symptoms.

Oncology experts discuss the rapid advancements in cancer diagnostics and treatments, emphasizing the need for equitable access and infrastructure improvements.

Payers cited high upfront costs, long-term uncertainty, and narrow coverage criteria as factors continuing to limit access and reimbursement innovation.

Attorney General Ken Paxton claims the manufacturers marketed acetaminophen toward pregnant women despite the “known dangers” to unborn children.

New data reinforce elinzanetant’s safety, efficacy, and ability to improve sleep disturbances in menopausal women, independent of vasomotor symptom relief.

Early and lifelong trauma can intensify menopause symptoms and accelerate cardiovascular and brain aging, according to research.

Preclinical data suggest a possible synergistic interaction between estrogen and GLP-1 signaling, explains Regina Castaneda, MD.

US safety data show that elinzanetant caused few adverse events and no new liver-related concerns in women, James Simon, MD, explains.

Hormonal shifts drive fat redistribution, muscle loss, and bone decline—all risk factors for cardiovascular disease in women, says Brooke Aggarwal, EdD.